Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 14/20 | 1.00 |
| ▸ | PPARG | P37231 | 11/20 | 1.00 |
| ▸ | PPARD | Q03181 | 6/20 | 1.00 |
| ▸ | MMP2 | P08253 | 3/20 | 0.56 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8160184 | 0.90 | PPARA (0.81) | PPARAPPARGPPARDMMP2SOAT1 | |
| SCHEMBL8151700 | 0.89 | PPARA (0.80) | PPARAPPARGPPARDMMP2 | |
| SCHEMBL8159724 | 0.87 | PPARA (1.00) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL14577557 | 0.86 | PPARA (0.85) | PPARAPPARGPPARDMMP2SOAT1 | |
| SCHEMBL8923385 | 0.82 | PPARA (0.70) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL8768954 | 0.82 | PPARA (0.69) | PPARAPPARGPPARD | |
| SCHEMBL8768663 | 0.82 | PPARA (0.69) | PPARAPPARGPPARDSOAT1 | |
| SCHEMBL8767856 | 0.81 | PPARA (0.68) | PPARAPPARGPPARD | |
| SCHEMBL6359838 | 0.81 | PPARA (0.68) | PPARAPPARGPPARDMMP2SOAT1 | |
| SCHEMBL8158047 | 0.81 | PPARA (0.67) | PPARAPPARGPPARDMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-12465564-B2 | Oral and nasal compositions and methods of treatment | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| US-20250339367-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-11-06 | — | — | US | disclosed |
| US-12403090-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| US-20250255780-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-08-14 | — | — | US | disclosed |
| US-12310922-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-12290597-B2 | Oral film compositions and dosage forms having precise active dissolution profiles | AQUESTIVE THERAPEUTICS, INC. (US) | 2025-05-06 | — | — | US | disclosed |
| US-12171723-B2 | System and method for making personalized individual unit doses containing pharmaceutical actives | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| EP-4422607-A1 | ORAL AND NASAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2024-09-04 | — | — | EP | disclosed |
| US-20240050317-A1 | SYSTEM AND METHOD FOR MAKING PERSONALIZED INDIVIDUAL UNIT DOSES CONTAINING PHARMACEUTICAL ACTIVES | AQUESTIVE THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | US | disclosed |
| WO-2002067912-A2 | METHOD FOR TREATING PPAR GAMMA MEDIATED DISEASES OR CONDITIONS | SMITHKLINE BEECHAM CORPORATION (US) | 2002-09-06 | — | — | WO | disclosed |
| WO-2002059098-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AS ACTIVATORS OF HUMAN PEROXISOME PROLIFERATOR ACTIVATED RECEPTORS | GLAXO GROUP LIMITED (GB) | 2002-08-01 | — | — | WO | disclosed |
| EP-1210345-A1 | OXAZOLE PPAR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2002-06-05 | — | — | EP | disclosed |
| EP-1189895-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2002-03-27 | — | — | EP | disclosed |
| EP-1102757-A1 | SUBSTITUTED OXAZOLE AND THIAZOLE DERIVATIVES AS HPPAR GAMMA AND HPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2001-05-30 | — | — | EP | disclosed |
| WO-2001017994-A1 | OXAZOLE PPAR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2001-03-15 | — | — | WO | disclosed |
| WO-2001000603-A1 | THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR PHARMACEUTICAL USE | GLAXO GROUP LIMITED (GB) | 2001-01-04 | — | — | WO | disclosed |
| US-6028109-A | Use of agonists of the peroxisome proliferator activated receptor alpha for treating obesity | GLAXO WELLCOME INC. (US) | 2000-02-22 | — | — | US | disclosed |
| WO-2000008002-A1 | SUBSTITUTED OXAZOLES AND THIAZOLES DERIVATIVES AS hPPAR GAMMA AND hPPAR ALPHA ACTIVATORS | GLAXO GROUP LIMITED (GB) | 2000-02-17 | — | — | WO | disclosed |
| WO-1997036579-A1 | USE OF AGONISTS OF THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA FOR TREATING OBESITY | GLAXO GROUP LIMITED (GB) | 1997-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034059-A1 | ORAL FILM COMPOSITIONS AND DOSAGE FORMS HAVING PRECISE ACTIVE DISSOLUTION PROFILES | SORD, SLC6A13, CACNA1A | PPARA 2061/4885PPARG 2056/4885PPARD 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.